Agenus to Present at the Cowen and Company 35th Annual Health Care Conference
February 25 2015 - 3:00PM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company
developing a broad portfolio of checkpoint modulators (CPMs) and
heat shock protein-based vaccines, as well as immune
adjuvants, today announced that the Company will present at
the Cowen and Company 35th Annual Health Care Conference on Monday,
March 2nd at 3:30 p.m. Eastern Time. The conference will take place
at The Boston Marriott Copley Place.
Webcast Information
The live and archived webcast of the presentation will be
accessible from the Company’s website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before each event to
ensure a timely connection. The archived replay will be available
on the Agenus website for one month following the conference.
About Agenus
Agenus is an immunology company developing a series of
immuno-oncology CPMs, heat shock protein peptide-based vaccines and
immune adjuvants. These programs are supported by three separate
technology platforms. Agenus’ checkpoint modulator programs target
GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s
proprietary discovery engine Retrocyte DisplayTM is used to
generate fully human and humanized therapeutic antibody drug
candidates. The Retrocyte Display platform uses a high-throughput
approach incorporating IgG format human antibody libraries
expressed in mammalian B-lineage cells. Agenus’ heat shock protein
vaccines have completed Phase 2 studies in newly diagnosed
glioblastoma multiforme, and in the treatment of herpes simplex
viral infection; the heat shock protein platform can generate
personalized as well as off the shelf products. The company’s QS-21
Stimulon® adjuvant platform is extensively partnered with
GlaxoSmithKline and Janssen Sciences Ireland UC and includes
several candidates in Phase 2, as well as shingles and malaria
vaccines which have successfully completed Phase 3 clinical trials.
For more information, please visit www.agenusbio.com, or connect
with the company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding the Company’s upcoming corporate
presentation. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission for the period ended September 30, 2014. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
Media:BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney/Jamie Maarten,
212-600-1902andrea@argotpartners.comjamie@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024